Part 1 (Phase Ia):
This is a dose escalation, 3 + 3 design study, to evaluate the safety and tolerability, and
to determine the RP2D of YL-13027 when administered b.i.d. in patients with advanced solid
tumors. Up to 4 cohorts of 3-6 patients each will be treated in part 1 of the study. One
cycle is 28 days.
Part 2:
This is a dose expansion phase to further evaluate the safety, tolerability and preliminary
anti-tumor activity of YL-13027 at the RP2D.